INDP Stock — Indaptus Therapeutics Inc.: Cash, EV, Pipeline

Share price

$3.55

Market cap

$473.0M

Cash

$11.6M

Enterprise value

$461.4M

Balance sheet

Cash	$11.6M
Debt	$0.0M
Net cash	$11.6M
Enterprise value	$461.4M
Basic shares	133.2M shares
Fully diluted shares	135.1M shares
Fully diluted market cap	$479.7M
Cash per share	$0.09

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading INDP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 11 - Sep 22	Decoy20	Phase 2	Solid Tumor, Adult; HCC - Hepatocellular Carcinoma; CRC (Colorectal Cancer)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Decoy20

Phase 1 · Terminated Modality: Systemically administered multi-TLR agonist immunotherapy

Target Toll-like receptors (multi-TLR agonist / danger signals)

Indications

Advanced/metastatic solid tumors (exhausted approved options) (Phase 1)

Status note Phase 1 dose-escalation/expansion trial (mono and combination with a tumor antigen) discontinued: no further enrollment, no participants remaining, and no active clinical development programs as of the 10-Q. Company is evaluating strategic alternatives for the Decoy20 program and broader business.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Decoy20
Lead indication	Solid Tumor, Adult
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05651022	Phase 2	Active, not recruiting	Sponsor	INDP	—	Solid Tumor, Adult; HCC - Hepatocellular Carcinoma; CRC (Colorectal Cancer)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Indaptus Therapeutics, Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

INDP — Indaptus Therapeutics Inc.